Over time, neurologists who specialize in multiple sclerosis (MS) have tended to tolerate less and less disease activity before they consider changing their patients’ therapies. “The concept that’s starting to emerge in the MS field is that of striving for no detectable disease activity,” said Jeffrey A. Cohen, MD, Director of Experimental Therapeutics at the Cleveland Clinic Mellen MS Center.
More Headlines